NYSEAMERICAN:CRMD - CorMedix Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.50
  • Forecasted Upside: 304.34 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.07
▼ -0.15 (-2.87%)

This chart shows the closing price for CRMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CorMedix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRMD

Analyst Price Target is $20.50
▲ +304.34% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CorMedix in the last 3 months. The average price target is $20.50, with a high forecast of $29.00 and a low forecast of $13.50. The average price target represents a 304.34% upside from the last price of $5.07.

This chart shows the closing price for CRMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in CorMedix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/21/2021JMP SecuritiesReiterated RatingBuy$19.00
10/5/2021JMP SecuritiesReiterated RatingBuy$19.00
8/24/2021JMP SecuritiesReiterated RatingBuy$22.00
5/14/2021Needham & Company LLCLower Price TargetBuy$31.00 ➝ $29.00
3/2/2021B. RileyReiterated RatingBuy$25.00 ➝ $13.50
2/17/2021Needham & Company LLCInitiated CoverageBuy$31.00
11/19/2020HC WainwrightReiterated RatingBuy
9/29/2020JMP SecuritiesInitiated CoverageMarket Outperform$22.00
9/21/2020TruistInitiated CoverageBuy$20.00
8/25/2020HC WainwrightReiterated RatingBuy$10.00
8/11/2020HC WainwrightLower Price TargetBuy$14.00 ➝ $10.00
7/9/2020HC WainwrightReiterated RatingBuy
5/12/2020B. RileyBoost Price TargetBuy$10.00 ➝ $12.00
3/18/2020B. RileyLower Price TargetBuy$15.00 ➝ $10.00
3/18/2020HC WainwrightReiterated RatingBuy$14.00
2/4/2020HC WainwrightReiterated RatingBuy$14.00
12/18/2019B. RileyReiterated RatingBuy
12/18/2019B. RileyInitiated CoverageBuy$48.00
12/2/2019HC WainwrightReiterated RatingBuy$14.00
5/28/2019HC WainwrightSet Price TargetBuy$14.00
3/18/2019HC WainwrightSet Price TargetBuy$15.00
1/18/2019HC WainwrightReiterated RatingBuy$17.50
12/12/2018HC WainwrightReiterated RatingBuy$17.50
12/6/2018Roth CapitalReiterated RatingBuy$6.00
12/6/2018Roth CapitalInitiated CoverageBuy ➝ Buy$30.00
10/15/2018HC WainwrightSet Price TargetBuy$15.00
8/15/2018HC WainwrightSet Price TargetBuy$15.00
7/26/2018HC WainwrightSet Price TargetBuy$15.00
5/23/2018HC WainwrightSet Price TargetBuy ➝ Buy$20.00 ➝ $10.00
4/2/2018HC WainwrightSet Price TargetBuy$20.00
10/16/2017HC WainwrightSet Price TargetBuy$20.00
9/25/2017HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $20.00
8/10/2017Rodman & RenshawLower Price TargetBuy ➝ Buy$25.00 ➝ $15.00
8/10/2017HC WainwrightSet Price TargetBuy$15.00
5/5/2017Rodman & RenshawLower Price TargetBuy$30.00 ➝ $25.00
4/24/2017FBR & Co.Reiterated RatingBuy
2/22/2017FBR & Co.Set Price TargetBuy$20.00
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 20 very positive mentions
  • 32 positive mentions
  • 12 negative mentions
  • 6 very negative mentions
7/30/2021
  • 28 very positive mentions
  • 27 positive mentions
  • 24 negative mentions
  • 7 very negative mentions
8/29/2021
  • 17 very positive mentions
  • 37 positive mentions
  • 25 negative mentions
  • 17 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/28/2021
  • 4 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
CorMedix logo
CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
Read More

Today's Range

Now: $5.07
Low: $4.98
High: $5.19

50 Day Range

MA: N/A

52 Week Range

Now: $5.07
Low: $4.36
High: $18.80

Volume

126,410 shs

Average Volume

577,463 shs

Market Capitalization

$193.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.43

Frequently Asked Questions

What sell-side analysts currently cover shares of CorMedix?

The following Wall Street sell-side analysts have issued stock ratings on CorMedix in the last year: B. Riley, JMP Securities, Needham & Company LLC, and Zacks Investment Research.
View the latest analyst ratings for CRMD.

What is the current price target for CorMedix?

3 Wall Street analysts have set twelve-month price targets for CorMedix in the last year. Their average twelve-month price target is $20.50, suggesting a possible upside of 304.3%. Needham & Company LLC has the highest price target set, predicting CRMD will reach $29.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $13.50 for CorMedix in the next year.
View the latest price targets for CRMD.

What is the current consensus analyst rating for CorMedix?

CorMedix currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRMD will outperform the market and that investors should add to their positions of CorMedix.
View the latest ratings for CRMD.

How do I contact CorMedix's investor relations team?

CorMedix's physical mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company's listed phone number is (908) 517-9500. The official website for CorMedix is www.cormedix.com.